Uncategorized

#AAD26: Sanofi reports underwhelming Phase 3 OX40 data in eczema, second case of Kaposi’s sarcoma

Published

1 week ago

on

Sanofi on Saturday shared more mixed efficacy results from a Phase 3 atopic dermatitis program for its anti-OX40 ligand monoclonal antibody, further eroding Wall Street’s already waning confidence in the candidate.

…

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version